Table 4.
Sample | Dose | Survival of cells |
||
---|---|---|---|---|
Hela | BHK-21 | Vero (Non-tumoral) | ||
In absence of solvent | 25 μL | 100% | 100% | 100% |
Presence of solvent | 25 μL | >95% | >95% | >95% |
α-Fe2O3 nanoparticles | 25 μL (30 mg/mL) | <5% | <5% | 10–20% |
Sample | Dose | Survival of cells |
||
---|---|---|---|---|
Hela | BHK-21 | Vero (Non-tumoral) | ||
In absence of solvent | 25 μL | 100% | 100% | 100% |
Presence of solvent | 25 μL | >95% | >95% | >95% |
α-Fe2O3 nanoparticles | 25 μL (30 mg/mL) | <5% | <5% | 10–20% |